GlaxoSmithKline PLC ADR (GSK NYSE) stock market data APIs
$46.9742
0.18(0.4%)
as of November 7, 2025
Try our APIs with
free plan!
GlaxoSmithKline PLC ADR Financial Data Overview
Price chart is built with
Anychart
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.
Prev. Close
46.9742
Open
47.1575
High
47.2227
Low
46.4726
52 wk Range
30.6792-47.21
Market Cap
93 699 M
P/E Ratio
13.438
Shares Outstanding
2 009 M
Revenue
32 166 M
EPS
1.4562
Dividends (Yield)
0.0362
Beta
0.231
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with GlaxoSmithKline PLC ADR (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GlaxoSmithKline PLC ADR data using free add-ons & libraries
Get GlaxoSmithKline PLC ADR Fundamental Data
GlaxoSmithKline PLC ADR Fundamental data includes:
- Net Revenue: 32 166 M
- EBITDA: 9 519 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-29
- EPS/Forecast: 1.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GlaxoSmithKline PLC ADR News
New
GSK CEO among candidates considered for Diageo leadership: FT
[Fortune Most Powerful Women Summit 2025 - Day 2] Leigh Vogel/Getty Images Entertainment Diageo (DEO [https://seekingalpha.com/symbol/DEO]) has considered a multitude of internal and external candida...
Evaluating GSK's 34% Rise as Pipeline Progress Sparks New Valuation Debate
Wondering if GSK is actually undervalued or if there's more to the story than recent headlines suggest? You're not alone, and we're about to dive into what those numbers really mean. Despite a slight ...
Lupus Nephritis Drugs Markets: A Global and Regional Analysis 2025-2035 - Unmet Needs in Lupus Nephritis Fuel R&D Investments and Market Growth
Company Logo Recent approvals of Benlysta and Lupkynis highlight a shift towards targeted therapies with improved profiles. Despite challenges like high costs and heterogeneous disease presentation, ...
Premenstrual Syndrome (PMS) Treatment Market: Global Industry Outlook with Company Analysis Report 2025-2033
Company Logo Factors like healthcare access, urbanization, and innovation, particularly in the U.S., France, and China, propel market expansion. Key players such as Pfizer, Bayer, and GlaxoSmithKline...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
